GlassScriptPhysician profile
Christopher John Sanchez
NPI 1588260285
$491.43
in general payments reported to CMS, 2019-2025
10 companies · $69.63 in 2025
The $69.63 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56.80 · 2024: $365 · 2025: $69.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $219.22 | 2024 | Daxxify |
| Abbvie INC. | $68.68 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.07 | 2024 | Airsupra |
| Gilead Sciences, INC. | $29.51 | 2023 | |
| Viiv Healthcare Company | $27.92 | 2024 | Apretude |
| Boston Scientific Corporation | $27.29 | 2023 | Watchman |
| Glaxosmithkline, LLC. | $26.97 | 2024 | Shingrix |
| Hologic Sales and Service, LLC | $19.97 | 2025 | Aptima |
| Lilly USA, LLC | $17.54 | 2025 | Zepbound |
| Seqirus USA INC | $17.26 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.